Cutaneous and mucocutaneous leishmaniasis.
Tegumentary leishmaniases are caused by approximately 15 species of protozoa of the genus Leishmania. They prevail in tropical and subtropical areas of the Old and New World but human mobility also makes them a medical problem in nonendemic areas. Clinical manifestations may comprise cutaneous and mucocutaneous forms that may be localized, disseminated, or diffuse in distribution and may differ in Old and New World leishmaniases. Diagnosis and treatment vary according to the clinical manifestations, geographic area, and Leishmania species involved. This article highlights the diversity and complexity of tegumentary leishmaniases, which are worsened by human immunodeficiency virus/Leishmania coinfection.
Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. hgoto@usp.br
Hiro
H
Goto
José Angelo
JA
Lauletta Lindoso
D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007891:Leishmania / Q000254:growth & development / Q000472:pathogenicity; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis / Q000473:pathology / Q000628:therapy / Q000635:transmission; D007897:Leishmaniasis, Mucocutaneous / Q000175:diagnosis / Q000473:pathology / Q000628:therapy / Q000635:transmission; D008403:Mass Screening / Q000379:methods; D014195:Travel
D000981:Antiprotozoal Agents